These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 21572149)

  • 21. Daily practice effectiveness of a step-down treatment in comparison with a tight step-up for early rheumatoid arthritis.
    Verschueren P; Esselens G; Westhovens R
    Rheumatology (Oxford); 2008 Jan; 47(1):59-64. PubMed ID: 18039681
    [TBL] [Abstract][Full Text] [Related]  

  • 22. "5D" Outcome in 52 patients with rheumatoid arthritis surviving 20 years after initial disease modifying antirheumatic drug therapy.
    Capell H; McCarey D; Madhok R; Hampson R
    J Rheumatol; 2002 Oct; 29(10):2099-105. PubMed ID: 12375318
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Contemporary disease modifying antirheumatic drugs (DMARD) in patients with recent onset rheumatoid arthritis in a US private practice: methotrexate as the anchor drug in 90% and new DMARD in 30% of patients.
    Sokka T; Pincus T
    J Rheumatol; 2002 Dec; 29(12):2521-4. PubMed ID: 12465145
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Adverse events with disease modifying antirheumatic drugs (DMARD): a cohort study of leflunomide compared with other DMARD.
    Cannon GW; Holden WL; Juhaeri J; Dai W; Scarazzini L; Stang P
    J Rheumatol; 2004 Oct; 31(10):1906-11. PubMed ID: 15468352
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Current aspects of cost effectiveness of TNF-alpha blocking agents in patients with rheumatoid arthritis].
    Merkesdal S; Ruof J
    Z Rheumatol; 2002; 61 Suppl 2():II/29-32. PubMed ID: 12491120
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Infliximab: a pharmacoeconomic review of its use in rheumatoid arthritis.
    Lyseng-Williamson KA; Foster RH
    Pharmacoeconomics; 2004; 22(2):107-32. PubMed ID: 14731052
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Modeling the 5-year cost effectiveness of treatment strategies including tumor necrosis factor-blocking agents and leflunomide for treating rheumatoid arthritis in the Netherlands.
    Welsing PM; Severens JL; Hartman M; van Riel PL; Laan RF
    Arthritis Rheum; 2004 Dec; 51(6):964-73. PubMed ID: 15593319
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Modelling cost effectiveness and cost utility of sequential DMARD therapy including leflunomide for rheumatoid arthritis in Germany: II. The contribution of leflunomide to efficiency.
    Schädlich PK; Zeidler H; Zink A; Gromnica-Ihle E; Schneider M; Straub C; Brecht JG; Huppertz E
    Pharmacoeconomics; 2005; 23(4):395-420. PubMed ID: 15853438
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Patient, disease, and therapy-related factors that influence discontinuation of disease-modifying antirheumatic drugs: a population-based incidence cohort of patients with rheumatoid arthritis.
    Maradit-Kremers H; Nicola PJ; Crowson CS; O'Fallon WM; Gabriel SE
    J Rheumatol; 2006 Feb; 33(2):248-55. PubMed ID: 16358365
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Methotrexate, hydroxychloroquine, and intramuscular gold in rheumatoid arthritis: relative area under the curve effectiveness and sequence effects.
    Hurst S; Kallan MJ; Wolfe FJ; Fries JF; Albert DA
    J Rheumatol; 2002 Aug; 29(8):1639-45. PubMed ID: 12180722
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cost effectiveness analysis of drug therapies for rheumatoid arthritis.
    Criswell LA; Such CL
    J Rheumatol Suppl; 1996 Mar; 44():52-5. PubMed ID: 8833053
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The comparison of trial data-based and registry data-based cost-effectiveness of infliximab treatment for rheumatoid arthritis in Sweden using a modeling approach.
    Lekander I; Kobelt G; Svarvar P; Ljung T; van Vollenhoven R; Borgström F
    Value Health; 2013; 16(2):251-8. PubMed ID: 23538176
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cost-effectiveness of treatment strategies using combination disease-modifying anti-rheumatic drugs and glucocorticoids in early rheumatoid arthritis.
    Wailoo A; Hernández Alava M; Scott IC; Ibrahim F; Scott DL
    Rheumatology (Oxford); 2014 Oct; 53(10):1773-7. PubMed ID: 24771112
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The Cost-effectiveness of Sequences of Biological Disease-modifying Antirheumatic Drug Treatment in England for Patients with Rheumatoid Arthritis Who Can Tolerate Methotrexate.
    Stevenson MD; Wailoo AJ; Tosh JC; Hernandez-Alava M; Gibson LA; Stevens JW; Archer RJ; Simpson EL; Hock ES; Young A; Scott DL
    J Rheumatol; 2017 Jul; 44(7):973-980. PubMed ID: 28202743
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cost effectiveness analysis of disease modifying antirheumatic drugs in rheumatoid arthritis.
    Osiri M; Kamolratanakul P; Maetzel A; Tugwell P
    Rheumatol Int; 2007 Sep; 27(11):1063-9. PubMed ID: 17440729
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Shared care or nurse consultations as an alternative to rheumatologist follow-up for rheumatoid arthritis (RA) outpatients with stable low disease-activity RA: cost-effectiveness based on a 2-year randomized trial.
    Sørensen J; Primdahl J; Horn HC; Hørslev-Petersen K
    Scand J Rheumatol; 2015; 44(1):13-21. PubMed ID: 25380077
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Two-year direct and indirect costs for patients with inflammatory rheumatic joint diseases: data from real-life follow-up of patients in the NOR-DMARD registry.
    Kvamme MK; Lie E; Kvien TK; Kristiansen IS
    Rheumatology (Oxford); 2012 Sep; 51(9):1618-27. PubMed ID: 22539479
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Medical resource use and costs among rheumatoid arthritis patients receiving disease-modifying antirheumatic drug therapy.
    Griffiths RI; Bar-Din M; MacLean CH; Sullivan EM; Herbert RJ; Yelin EH
    Arthritis Care Res; 2000 Aug; 13(4):213-26. PubMed ID: 14635276
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy, tolerability and cost effectiveness of disease-modifying antirheumatic drugs and biologic agents in rheumatoid arthritis.
    Nurmohamed MT; Dijkmans BA
    Drugs; 2005; 65(5):661-94. PubMed ID: 15748099
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Economic consequences and potential benefits.
    Fautrel B; Verstappen SM; Boonen A
    Best Pract Res Clin Rheumatol; 2011 Aug; 25(4):607-24. PubMed ID: 22137927
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.